

Unit Form (Mandatory : Fill in one form for each unique unit/room included in the survey)

Date of survey		Person(s) completing form (Auditor	
(dd/mm/year)	//	code) (optional)	
Name institution:		Unit Name	
		Room name(s) (optional)	

Type of speciality - Tick just <u>"one"</u> most appropriate type of outpatient unit									
EM (Emergency)	□ GM (General (Internal) Medicine mixed) ¹	□ HCP (Healthcare Practice)							
OB (Observation)	SM (Surgical Mixed)	□ GP (General Practitioner practise)							
RESP (Respiratory)	HO (Haematology-Oncology)	MAL (Malnutrition)							
ID (Infectious disease)	PLAS (Plastic Reconstructive Surgical)	NM (Neonatal Medical)							
HIV/TB (HIV-Tuberculosis)	ORT (Orthopaedic)	ANC (Antenatal care)							
REN (Nephrology-urology)	ENT (Ear Nose and Throat)	GYN (Gynaecology)							
DIAL (Dialyses)	EYE (Ophthalmology)	OBST (Obstetrics)							
□ GAS (Gastroenterology)	ENDO (Endoscopy)	DEN (Dental Clinic)							
	STI (Sexually Transmitted Infection)								

Total number of prescribers ² on the unit/room during defined timeslot of the survey								
N doctor(s) N nurse		e(s)	N pharmacist(s)		N other(s)			
Timeslot data gathering on the	dav of	Starting time ³ (hour):		O a.m.	O p.m. (tick as appropriate)			
	survey ⁴	Ending time ³ (hour):		O a.m.	O p.m. (tick as appropriate)			

¹ Includes specialties such as Dermatology, Allergy-Immunology, Cardiovascular, etc. General medicine mixed refers also to paediatrics in general. Tick as well if no specialty is defined.

² Specify the profession of person(s) "prescribing" antimicrobials and the number of them included in the survey on the unit/room during the defined timeslot of the survey.

³ Specify approximate starting hour (e.g. 8 a.m.) and approximate ending hour (e.g. 3 p.m.)

⁴ Survey the unit for at least 4 hours; or about a half a day (unless session is shorter, in which case, survey for the whole ses*sion duration)*. Preferably start the survey at the beginning of the session.



OUTPATIENT F	orm: Complete	e for <u>every</u> out	patier	nt seen	on the	unit/ro	oor	n and r	not admitt	ed >24 ho	urs or slo	e <mark>pt ove</mark>	ernight <u>d</u>	<u>uring the ti</u>	<u>meslc</u>	<u>ot of sur</u>	<u>vey</u> 1
Name/code of unit	Name/code room within t		Unique patient ide			identifi	entifier or sequential number ²			r ²	Survey Number ³						
Patient age group (tick as appropriate)OAdult ≥18 years OOChild ≤17 years O				sex	Sex M, F, U Test ordered (tick as appropriate) ⁴ O Biomarker O POCT / RDT / malaria microscopy O UNK Admiss statu												
Presenting symptoms or main reason(s) consultation on the day of the survey (tick if present, multiple choice, max. 6 choices) O Temperature >=38.3°C/>=101°F O Sub-febrile temperature (<38.3°C/<101°F) O Sneezing/nasal congestion/runny or stuffy nose O Acute cough O Chronic cough O Sore throat O Dyspnoea, difficult breathing O Ear pain O Ear discharge O Eye discharge/red/swollen eyes O Chest pain O Musculoskeletal pain O Headache O Fatigue/lethargy/general body weakness O General body pain O Confusion O Dizziness O Seizures O Diarrher O Bloody diarrhea O Painful/frequent urination O Abdominal pain O Nausea/vomiting O Toothache/gum swelling O Limb swelling/warmth erythem O Itch or other symptoms of genitals/anus O Skin lesions/spots O Wound/ulcer/burns O Trauma O Other symptom(s) O Unknown O None, other red)iarrhea rythema									
	To <u>complete o</u>		patien	1											-		
	tailed patient age* Ionths (1-23month)		nth)				in the second									Yes 0 No	
Years (≥2years) N	ionuns (1-23monun)		intri)	weight* (in kg) kg, r			onut	nate only) allergy?			,					0 Unknown 0 Blood 0 Other	
Treatment based on bio	marker data) Yes	0 No		1	Г		Treatmon	t based on P							
If yes, which biomarke				alue	Uni	i t ⁹	-					1 1		<u>אַקי</u> 2	1	0 Yes 0 No 3	
WBC, serum lacta						, c		If yes, s	specify whic	h (max. 3) ¹⁰	(max. 3) ¹⁰		£				
Type biological sample (Blood/urine/other)				Result, specify ¹			ify ¹¹	¹¹ 0 Pos. 0 Neg. 0 Inc. 0 Po			Pos. 0 Neg. 0	os. 0 Neg. 0 Inc. 0 Pos. 0 Neg. 0 Inc.					
Underlying morbidity (multiple choice, max. 3 choices) None Diabetes mellitus, type 1 or 2 Diabetes mellitus, type 1 or 2 Hematological or solid cancer/ Recent chemotherapy (<3months) Post-COVID ¹² Malnutrition ¹³ None Diabetes mellitus, type 1 or 2 Immunosuppressed not oncology Immunosuppressed not oncology Chronic lung diseases (incl. cystic fibrosis, COPD, bronchiectasis, asthma) Trauma Chronic renal failure (incl. patients on dialysis) Unknown 																	
Antimicrobial (AM) (gen	eric) Name		1.	1.			2.		3.	3.		4.		5.	5.		
Specify: new, on- going, switch 15If ongoing/switch, where obtained?(Here, HCF, Pharm, Self, else, U)15Single Unit Dose 16Unit (g, mg, IU, MU) 16		•															
N Doses/day ¹⁷	10.	R, I, IM, IV) ¹⁸															
Intended duration prescription in N days/UNK																	
Clinical diagnosis (see appendix I)																	
Type of indication (see appendix II)																	
Reason in notes (Yes, No, Not assessable) ¹⁹																	
Local guideline exists for diagnosis (Y, N, NI, U) ²⁰																	
If yes (guideline exists),																	
Drug according to guideline (Y, N, NA, U)																	
Dosing according to guideline (Y, N, NA, U)			J)														

Note: * Detailed patient age, Current weight, Birth weight, 'If ongoing, where previously prescribed' are **optional variables**.

Route of Adm. according to guideline (Y, N, NA, U) **Duration according to guideline** (Y, N, NA, U)

¹ Not admitted >24 hours or slept overnight during the timeslot of survey: However, include patients on emergency and observation units awaiting transfer to an inpatient ward and may be occupy a bed >24 hours before the survey. Complete an outpatient form for these patients as well; these patients count in the numerator and denominator. Patient Identifier: A unique patient identifier or sequential attributed number or code which will not be included in the online database. Survey Number: A unique non-identifiable number given by WebPPS. Leave blank but note down the number after the patient data has been recorded in the online database. Test ordered: Specify if a biomarker, Point-of-Care Test (POCT), Rapid Diagnostic Test (RDT) or (malaria) microscopy test was ordered for this patient. 5 Detailed patient age: If the patient is \geq 2 years, specify only the number of years, if between 1 and 23 months specify only number of months, if < 1 month specify only number of days. Penicillin allergy confirmed: confirmed penicillin allergy is confirmed by Skin testing for penicillin allergy with penicillin G (Pen G), penicilloic acid (PA), and penicilloy poly-L-lysine (PPL) i Cultures taken before start antimicrobial: specify whether a culture was taken before an antimicrobial was administered to the patient. If yes, specify additionally which one: Blood culture or Other culture. ⁸ If "treatment based" on biomarker, specify which one: CRP (C-reactive protein), PCT (Procalcitonin), WBC (white blood cell count), or serum lactate (obtained from Arterial or Venous Blood Gas). Do not report a biomarker test if it did not contribute to the chosen antimicrobial treatment. The unit for the biomarker CRP or PCT value expressed in mg/L, µg/L, ng/L, ng/dL, ng/mL, µg/mL, nmol/L. In thousand per microliter (µL) for WBC count (normal number of WBCs in 9 the blood is 4,500 to 11,000 WBCs per microliter). The unit for serum lactate is expressed as mmol/L (normal range in adults: 0.5-2.2 mmol/L for venous blood; 0.5-1.6 mmol/L for arterial blood). For conversion calculator see: http://unitslab.com/node/67 (CRP) and http://unitslab.com/node/103 (procalcitonin): https://unitslab.com/node/152 (serum lactate) 10 Treatment based on POCT, RDT or malaria microscopy: Do not report any test if it did not contribute to chosen antimicrobial treatment. If Yes, specify up to 3 single POCT/RDT/microscopy tests: \geq HIV, \triangleright **TB** (includes MTB/RIF (detects MTB and rifampicin (RIF) resistance simultaneously) or \geq HepB (Hepatitis B), Scrub typhus POCT, \geq Malarial antigen testing, MTB/XDR (detects resistance to isoniazid, fluoroguinolones, amikacin, kanamycin, capre- \triangleright \geq Strep A. omvcin and ethionamide). \geq Syphilis POCT. **GBS** (Intrapartum or antepartum Group B Streptococcus RDT), SH (Sexual Health RDT), \geq MRSA RDT, \geq Dengue RDT SARS-CoV-2, Flu/RSV (Rapid detection and differentiation of Flu A, Flu B, or RSV), \triangleright Other. \geq

¹¹ <u>Results biomarker</u>: please indicate whether the result was **Pos.=**positive: e.g. when parasites were seen; **Neg.=**negative: e.g. when no parasites were seen; or **Incl.=**inconclusive: e.g. if it is unknown whether parasites were seen, or when insufficient high-power fields/white blood cells/RBCs were seen or counted, or when the quality control failed, or for another reason.

¹² Post-COVID refers to symptoms lasting >2 months after initial COVID-19 infection with new symptoms developing >3 months post-infection.

¹³ Malnutrition refers to dietary deficiency which lead to lack of vitamins, minerals and other essential substances. Score illnesses as marasmus, kwashiorkor, scurvy, delayed growth, etc.

¹⁴ Specify by prescription/course: "New" refers to newly prescribed antimicrobials, not changed from a previous antimicrobial treatment that was prescribed for the same condition/complaints. "Ongoing" refers to antimicrobial treatments that are still continuing but are not changed by the prescriber. "Switch" is switched to an other antimicrobial and refers to antimicrobial treatments that were changed from a previous antimicrobial treatment that was prescribed for the same condition/complaints.

- ¹⁵ <u>If ongoing, where prescribed</u>: "Here" refers to the current attending institution. "HCF" (other healthcare facilities) refer to any hospital departments, outpatient clinics (including dental and day surgery clinics), or primary or community healthcare centers or general practitioner. "Pharmacy" refers to 'over-the-counter' use of antimicrobials <u>without prescription</u>. "Self-medication" refers to any previously administered antimicrobial (include all antimicrobials, <u>exclude</u> analgesics or painkillers, or anti-inflammatory drugs) <u>without prescription</u> (e.g. leftovers at home, received from family/friends).
- ¹⁶ <u>Single Unit Dose</u>: Numeric value for dose per administration and unit for the dose (in grams, milligrams, IU or MU)
- ¹⁷ <u>N Doses/day</u>¹ If necessary provide fractions of doses: (e.g., every 16h = 1.5 doses per day, every 36h = 0.67 doses per day, every 48h = 0.5 doses per day).
- ¹⁸ <u>Route</u>: Routes of administration are: Oral=**O**; Rectal=**R**; Inhalation=**I**; Intramuscular=**IM**; Intravenous=**IV**.
- ¹⁹ <u>Reason in Notes</u>: A diagnosis / indication for the antimicrobial course is recorded in the patient's documentation (treatment chart, notes, etc.). Y=Yes; reason recorded in notes. N=No; reason not recorded in notes. Not assessable because e.g. no patient file was recorded in the institution.
- ²⁰ <u>Guideline existing</u>: A guideline can be a local, national or any other adopted guideline. Y=Yes; N=No; no guidelines for the specific indication. NI=No Information; because diagnosis/indication is unknown; U=Unknown.
- ²¹ <u>Guideline compliance</u> according to the Drug=type or choice of the antimicrobial; Dosing=the dosing of chosen antimicrobial; Route of Adm.=the route of administration; and Duration=the duration of the therapy/prophylaxes. Y=Yes; compliant to the guideline. N=No; Not compliant to the guideline. NA=Not Available; because information is missing in the guideline; U=Unknown.

¹ Sullivan TJ, Wedner HJ, Shatz GS, Yecies LD, Parker CW. Skin testing to detect penicillin allergy. J Allergy Clin Immunol. 1981 Sep;68(3):171-80. doi: 10.1016/0091-6749(81)90180-9. PMID: 6267115

Site	Codes	Examples					
CNS	Proph CNS	Prophylaxis for CNS (meningococcal)					
	CNS	Infections of the C entral N ervous S ystem					
EYE	Proph EYE	Prophylaxis for Eye operations					
	EYE	Therapy for Eye infections e.g., Conjunctivitis, trachoma, blepharitis, keratitis					
ENT	Proph ENT	Prophylaxis for Ear, Nose, Throat including mouth (Surgical or Medical prophylaxis)					
	PHAR	Therapy for pharyngitis					
	SIN	Therapy for sinusitis					
	AOM	Acute otitis media and CSOM (Chronic Suppurative Otitis Media)					
	ENT	Therapy for Ear, Nose, Throat infections, other than PHAR, SIN or AOM					
DEN	Proph DEN	Prophylaxis for dental cases					
	DEN	Dental infections e.g. abscess, pulpitis, periodontal disease					
RESP	Proph RESP	Prophylaxis for Respiratory pathogens e.g. for aspergillosis					
	LUNG	Lung abscess including aspergilloma					
	URTI	Upper Respiratory Tract viral Infections including influenza but not ENT					
	Bron	Acute Bronchitis or exacerbations of chronic bronchitis					
	Bronch	Acute bronchiolitis					
	Pneu	Pneumonia or LRTI (lower respiratory tract infections)					
	COVID-19	Coronavirus disease caused by SARS-CoV-2 infection					
	ТВ	Pulmonary TB – Tuberculosis / Extrapulmonary TB					
	CF	Complication of cystic fibrosis					
CVS	Proph CVS	Cardiac or Vascular prophylaxis, endocarditis prophylaxis					
	CVS	CardioVascular System infections: endocarditis, endovascular device e.g pacemaker, vascular graft					
GI	Proph GI	Gastro-Intestinal prophylaxis					
	GO	Acute Infectious Diarrhoea, gastroenteritis (ref https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2022.02)					
	GI	Any other Gastro-Intestinal infection					
	CDIF	Clostridioides difficile infection					
SSTBJ	Proph SST	Prophylaxis for Skin and Soft Tissue, impetigo, plastic or orthopaedic surgery					
	SST	Skin and Soft Tissue: Cellulitis, impetigo, erysipelas, folliculitis, other viral exanthems, burn wound-					
		and bite-related infections.					
	Sys-DI	Disseminated infection (viral infections such as measles, Cytomegalovirus)					
	DST	Deep Soft Tissue not involving bone e.g., infected pressure or diabetic ulcer, abscess					
UTI	Proph UTI	Prophylaxis for recurrent Urinary Tract Infection (Medical Prophylaxis)					
	Cys	Lower Urinary Tract Infection (UTI), cystitis					
	Руе	Upper UTI including catheter related urinary tract infection, pyelonephritis					
	ASB	Asymptomatic bacteriuria					
GUOB	Proph OBGY	Prophylaxis for OBstetric or GYnaecological surgery (MP: carriage of group B streptococcus)					
	OBGY	Obstetric/Gynaecological infections, Sexually Transmitted Diseases (STD) in women, vaginitis, vaginosis					
	GUM	Genito-Urinary Males + Prostatitis, epididymo-orchitis, STD in men					
No de-	BAC	Bacteraemia or fungaemia with no clear anatomic site and no shock					
fined site	SEPSIS	Sepsis of any origin (eg urosepsis, pulmonary sepsis etc), sepsis syndrome or septic shock with no clear anatomic site. Include fungaemia (candidemia) with septic symptoms					
(NDS)	Typh-fever	Typhoid fever/enteric fever					
(Malaria						
	HIV	Human immunodeficiency virus					
	PUO	Pyrexia of Unknown Origin - Fever syndrome with no identified source or site of infection					
	LO-LYMPH	Localized acute lymphadenitis					
	LYMPH	Lymphatics as the primary source of infection. Suppurative lymphadenitis					
	Other	Antimicrobial prescribed with documentation but no defined diagnosis group					
	MP-GEN	Drug is for Medical <i>Prophylaxis</i> in general, targeting no specific site, e.g. antifungal prophylaxis					
	UNK	Completely Unk nown Indication					
	PROK	Antimicrobial (e.g. erythromycin) prescribed for Prok inetic use					
I							

Appendix I – Clinical diagnostic codes (what the clinician aims at treating)

APPENDIX II - Type of Indication

<u>CAI</u> Community acquired infection	Concerns any infection acquired in the community, thus outside the healthcare setting in a patient without recent (<48hours) health care exposure.								
HAI	HAI1 Post-operative surgical site infection (within: 30 days of surgery OR; 90 days after implant surgery)								
Healthcare Associated Infection following admission and/or intervention during	HAI2 The patient has been discharged from hospital < 48 hours and has a known hospital infection or a new infection < 48 hours after discharge from hospital . The infection can be an intervention related (e.g. intravenous or urinary catheter-related) or any other hospital acquired infection of mixed or undefined origin.								
hospital stay	<u>HAI3</u> <i>C. difficile</i> associated diarrhoea (CDAD) (>48 h post-admission or <30 days after discharge from previous admission episode).								
Surgical prophylaxis*	SP1Single doseSP2one daySP3>1 day								
For surgical patients the duration of prophylaxis should be encoded as either prescription of one dose, one day (= multiple doses given within 24 hours) or prescribed >1 day.									
MP Medical prophylaxis	For example long term use to prevent UTI's or penicillin in asplenic patients etc.								
<u>ОТН</u> Other	For example erythromycin as a motility agent (motilin agonist).								
<u>UNK</u>	Completely unknown indication								

Select 1 possibility for each reported antimicrobial

*Surgical prophylaxis includes those antibiotics prescribed on the day of the survey for a **day-case surgical intervention, including dental procedures**.

Appendix III: Combination anti-infective agents

Combinations of an antibiotic and a beta-lactamase inhibitor:

Ampicillin and beta-lactamase inhibitor: report only ampicillin dose (J01CR01)

Amoxicillin and beta-lactamase inhibitor: report only amoxicillin dose (J01CR02)

Example:

Amoxicillin and beta-lactamase inhibitor 1.2g IV → 1g (amoxicillin) + 200mg (clavulanic acid), report 1 g as a dose

Other combinations of multiple antimicrobial substances:

J01EE01 Sulfamethoxazole and Trimethoprim: **report the total amount of sulfamethoxazole and trimethoprim** Example: Co-trimoxazole 960mg: (sulfamethoxazole. 800mg + trimethoprim 160mg), **report 960mg**